In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide HGH (somatotropin) | Synthetic analog GHRP-6 | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 1,108 | 942 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 110 (108 in people) | 32 (11 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 358 · 32 active72 more mention it but do not test it | None registered | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Genotropin says: “Replacement in adults with adult-onset or childhood-onset GHD”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | HGH (somatotropin) | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Nervous system and cognition | 1069115 | 377117156 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Linear growthMusculoskeletal | 1301264 | 44 |
|---|
| Bone and jointMusculoskeletal | 12611511 | 1111 |
|---|
| Body compositionWhole body | 109109 | 66 |
|---|
| Glycemic controlMetabolic and weight | 8585 | 183132 |
|---|
| LipidsMetabolic and weight | 7373 | 99 |
|---|
| Receptor activity and mechanismNervous system and cognition | 2626 | 190167122 |
|---|
| Adverse eventsWhole body | 60582 | 20614 |
|---|
| Body weightMetabolic and weight | 46415 | 1616 |
|---|
| Heart functionCardiovascular | 4040 | 2222 |
|---|
| Exercise and physical functionWhole body | 4141 | 33 |
|---|
| Protein and amino acid metabolismMusculoskeletal | 3131 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
GHRP-6 differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 358 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S712 participantsJul 2007 to Dec 2008
Chronic Kidney Disease · End-Stage Renal Disease
EMD Serono326 participants28 May 2004 to 28 Sept 2005
HIV Infections · Lipodystrophy
Pfizer316 participantsDec 2006 to Aug 2012
Idiopathic Short Stature
72 more mention it but do not test it. They only measure it or name it in their text.
No registered trial that tests GHRP-6 found in ClinicalTrials.gov.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | HGH (somatotropin) | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in cm/year | 9.78 cm/year Height velocity · somatropin at month 12 Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022 | No comparable result 15 randomized-trial results measure it in another way or another unit. |
| Wound healingSkin and woundCompared as: value in the arm that got the peptide, in days | 6.8 days Healing time Placebo mean: 8.5 days Dose studied: 0.2 mg/kg/dayn = 461994 | |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 79.1% Treatment-emergent adverse events Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022 |
9.78 cm/year
Height velocity · somatropin at month 12
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022
No comparable result
15 randomized-trial results measure it in another way or another unit.
No randomized trial result
10 results from other study designs.
No randomized trial result
20 results from other study designs.
6.8 days
Healing time
Placebo mean: 8.5 days
Dose studied: 0.2 mg/kg/dayn = 461994
No randomized trial result
10 results from other study designs.
79.1%
Treatment-emergent adverse events
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022
No randomized trial result
20 results from other study designs.